Spots Global Cancer Trial Database for A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Official Title: A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors

Study ID: NCT00612209

Conditions

Cancer, Advanced Solid Tumors

Interventions

ARQ 197

Study Description

Brief Summary: This is an open label, single arm, dose escalation study of ARQ 197 in patients with advanced solid tumors.

Detailed Description: Patients will take ARQ 197 orally twice daily continuously at dose levels specified for their respective dose cohorts. The ARQ 197 starting dose will be a total daily dose of 200 mg (100 mg bid). ARQ 197 treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted. A treatment cycle is designed as four weeks (28 days) and will be repeated without therapy interruption.